Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
Patients’ demographics and physiological characteristics influence whether they will accept a switch from an originator drug to a biosimilar, according to findings from a New Zealand study.
For example, being a woman was a strong predictor of concern about a biosimilar switch (P < .001), they said. “Gender was significantly correlated with perceptions of a biosimilar's safety. Female patients were more concerned about switching from a bio-originator to a biosimilar [P < .001].”
Patients who perceived they are highly sensitive to medicines were less likely to accept a biosimilar switch (P = .001), and those with a habit of looking health information up on the internet were more likely to be concerned about switching (P = .001), the investigators said.
In addition, patients who had strong emotional responses to their health condition were less likely to perceive biosimilars as safe or to consider switching from originator drugs, although these findings were not statistically significant.
Investigators enrolled 96 patients taking originator drugs for rheumatic diseases. Patients were asked to watch a video tutorial explaining biosimilars and their equivalence to originator drugs and then given a survey to gauge their receptiveness to biosimilars.
The average patient was aged 54 years and college educated (64%); most were women (69%). The most common originator therapy was rituximab (35%), and the most frequent condition rheumatoid arthritis (65%).
A strong negative association for biosimilar safety was observed among those who had taken the originator product for only a short time (P = .002).
The investigators said their findings were consistent with previous studies. “Interestingly, the study findings show that concerns about switching to a biosimilar are exacerbated in patients who have stronger emotional responses to their condition. This is an important finding as negative affective responses, such as anger or fear, are common in patients with arthritis but can bias treatment decision-making and risk perceptions.”
They added that the finding about strong emotions and biosimilar rejection suggests that efforts to improve patient coping skills and resilience may pay off.
Past studies also have shown that patients with high levels of health anxiety and perceived sensitivity to medicines tend to search for information online. One concern is patients may access incorrect information. Providers should step in after a switching discussion with “credible material” to help support the switch, the authors said.
A patient’s experience with the originator product, in terms of effectiveness and adverse events, is also a factor in biosimilar acceptance. Providers need to “assess and reassure patients who have had unfavorable experiences with biosimilars,” the investigators said.
The study was important because biosimilars are equivalent to originators in terms of safety and efficacy, and they have the potential to bring down the costs of health care. Knowing which patients are less likely to be accepting of a switch to a biosimilar can allow for interventions, the investigators said.
Reference
Gasteiger C, Lobo M, Dalbeth N, Petrie KJ. Patients’ beliefs and behaviors are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatol Int. Published online April 16, 2020. doi:10.1007/s00296-020-04576-7
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.